Immune Pharmaceuticals
New York
About Immune Pharmaceuticals
Immune Pharmaceuticals Inc. (NASDAQ OMX First North Premier: IMNP; OTCQX: IMNP,) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The company’s lead product candidate, Bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $62.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2017)
- Ticker: nasdaq:IMNP
- Website: immunepharmaceuticals.com
- Phone: 914-606-3500
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/immune-pharmaceuticals-2241650 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.